• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20092 / Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283...

Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283 in Childhood Cancers

11 February 2009/in 2009, News

Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283 in Childhood Cancers

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2009-02-11 12:48:542016-11-28 12:49:23Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283 in Childhood Cancers

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen’s PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia Link to: SuperGen’s PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia SuperGen’s PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models... Link to: Astex Scientists Solve Structure of Cyclin Dependent Kinase 4 Link to: Astex Scientists Solve Structure of Cyclin Dependent Kinase 4 Astex Scientists Solve Structure of Cyclin Dependent Kinase 4
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok